1. Md. Fakruddin, Zarifah Chowdhury, Sayed Ul Alam Shibly, SM Bakhtiar Ul Islam, Jinath Sultana Jime, Nayeema Bulbul, Mohammad Badrul Anam, Khanjada Shahnewaj Bin Mannan, Md. Asaduzzaman Shishir (2024). Microbial Avengers: How Microorganisms Drive Angiogenesis for Good and Bad? Journal of Angiotherapy, 8(5), 1-10, 9650. https://publishing.emanresearch.org/Journal/FullText/5403

2. Sanjana Mahbub Supty, Tarif Md Faiyaz Saadat, Khondoker Tanjim Islam, Rafid Nahian Rubaiyat, Khadijatul Kubra, S M Bakhtiar UL Islam (2023). Multidrug Resistance and Molecular Characterization of Klebsiella spp. Isolated from the Cloacal Samples of Broiler Chickens in Bangladesh, Microbial Bioactives, 6(1), 1-11, 9419. https://publishing.emanresearch.org/Journal/JustAcceptedAbstract/5221

3. Tasbir Amin, Kazi Rahman, Md Fakruddin, Islam S M Bakhtiar UL. Transglutaminase 2: A keystone in the molecular puzzle of cancer. CP 2023, 5(2), 2495. https://accscience.com/journal/CP/5/2/10.36922/cp.2495

4. Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase. Islam, S.M.B.U.; Hong, Y.M.; Ornella, M.C.; Ngabire, D.; Jang, H.; Cho, E.; Kim, E.-K.; Hale, J.J.J.; Kim, C.H.; Ahn, S.C.; Cho, M.; Hwang, T.-H. Biomedicines 2020, 8, 426. https://pubmed.ncbi.nlm.nih.gov/33081279/

5. Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase. S M Bakhtiar UL Islam, Bora Lee, Fen Jiang, Eung-Kyun Kim, Soon Cheol Ahn, Tae-Ho Hwang.Cancers. 2020, 12, 228. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016767/

6. Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB and CES2 Euna Cho, S M Bakhtiar UL Islam, Fen Jiang, Ju-Eun Park, Bora Lee, Nam Deuk Kim, Tae-Ho Hwang. Cancer Res Treat. 2020 Jan;52(1):309-319. doi: 10.4143/crt.2019.161. Epub 2019 Aug 6. https://pubmed.ncbi.nlm.nih.gov/31401821/ 

7. Emergency endoscopic variceal ligation in cirrhotic patients with blood clots in the stomach but no active bleeding or stigmata increases the risk of rebleeding. Su Jin Kim, Cheol Woong Choi, Dae Hwan Kang, Hyung Wook Kim, Su Bum Park, Young Mi Hong, Ki Tae Yoon, Mong Cho, Hyung Seok Nam, SM Bakhtiar UI Islam. Clin Mol Hepatol 2016;22:466-476. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266350/ 

8. Bone marrow metastasis presenting as bicytopenia originating from hepatocellular carcinoma.Young Mi Hong, Ki Tae Yoon, Mong Cho, Dae Hwan Kang, Hyung Wook Kim, Cheol Woong Choi, Su Bum Park, Jeong Heo, Hyun Young Woo, Won Lim, SM Bakhtiar UI Islam. Clin Mol Hepatol 2016; 22(2): 267-271. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946406/ 

9. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL expressing oncolytic adenovirus through enhanced viral replication and cellular arrest. Kang S, Kang D, Bakhtiar Ul Islam SM, Je S, Kim JH, Song JJ. Cell Signal. 2015 Jun;27(6):1214-24. https://pubmed.ncbi.nlm.nih.gov/25748050/ 

10. Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Jeong JH, Cho BC, Shim HS, Kim HR, Lim SM, Kim SK, Chung KY, Islam SB, Song JJ, Kim SY, Kim JH. J Korean Med Sci. 2013 Jul; 28(7):1005-1014. https://pubmed.ncbi.nlm.nih.gov/23853482/ 

11. Antimicrobial, antioxidant, and cytotoxic activities of Bixa orellana Linn. S.M. Bakhtiar Ul Islam, Md. Khalid Hossain, Isidore Gomes, Donald James Gomes, Sabita Rezwana Rahman, Mohammad S. Rahman and Mohammad A. Rashid. Lat. Am. J. Pharm. 30 (6): 1126-1134(2011). http://www.latamjpharm.org/resumenes/30/6/LAJOP_30_6_1_13.pdf 

Awards

International Abstract Award (46th Annual Meeting of Korean Cancer Association and the 6th International Cancer Conference), 2020.

Pusan National University International Student Scholarship, 2016-2020.

Training awards, Yonsei University College of Medicine, Korea, 2012 - 2013. 

Umea University Research Scholarship, 2010-2011.

Rajshahi Education board, Bangladesh, 2000.

Rajshahi Education board, Bangladesh, 1997.

Certification

Introduction to informed consent. The Global Health Network, December 2022

European Compliance Academy (ECA), Heidelberg, Germany. GMP for Vaccine Manufacturers, 2021.

World Health Organization (WHO), Switzerland. Virtual cGMP Training Marathon for Vaccine Manufacturing. Duration: Two months, 2021. 

American Society of Clinical Oncology: ASCO University, USA. Immuno-Oncology Program, 2018.

Training

State-of-the-art bio-pharmaceutical license training workshops, KoBIA. South Korea, 2016

Korean Technical Seminar. Bioreliance, South Korea, 2015.   

Cancer Epidemiology, icddr,b, 2014.  

Ph.D. in Medical Science  (Major:Microbiology & Immunology), Pusan National University, South Korea.

MSc. in Molecular Biology, Umea University, Sweden.

MSc. in Microbiology, University of Dhaka, Bangladesh.

BSc. in Microbiology, University of Dhaka, Bangladesh.

Senior Research Scientist, Medical Research Center, Pusan National University, South Korea, 2016~2020.

Researcher, Cancer Center, Yonsei University Health System, South Korea, 2012~2013.   

Part-time Lecturer, Department of Microbiology, Jahangirnagar University, Bangladesh, 2011~2012.

Researcher, Department of Clinical Microbiology, Umea University, Sweden, 2010~2011. 

Deputy Manager, Biologics, business development & corporate affairs, Beximco Pharmaceuticals Ltd. Bangladesh, 2021~2022.

Role and responsibilities: 

• Design, and facility development for R&D, and quality control laboratory for biologics GMP fill and finish activity.
• Single handed, and successfully obtained approval from the top management for exclusive designing of a R&D and QC laboratory within six months.
• R&D and Quality control (tissue culture, virus culture, molecular biology, immunology, proteomic and microbiology) Laboratory design, and preparation of equipment list for the respective sectors.
• International collaboration for potential vaccine (bulk) partners which may lead to further fill and finish business opportunity.
• Provide training to team members, and communication with international vendors, and consultants.

R&D Team Leader, Bionoxx Inc. South Korea, 2016~2020.

Role and responsibilities:

• Bionoxx Inc. is a spin-off from Pusan National University Medical Research center, South Korea.
• Contributed as an inital team member for the development of this statrt-up biotechnology company and also act as R&D team leader.
• Academia to industry collaboration, novel virus-based drug engineering and technology transfer.
• Viral and non-viral vector engineering, characterization, in vitro and in vivo effect validation.
• Extensive cytotoxiciy assay in NCI-60 listed human cancer cell lines as well as primary cell lines.
• Stable cell line generation, and in vivo gene therapy using genetically modified oncolytic viruses.

Scientist, Sillajen Inc. South Korea, 2014~2015. 

Role and responsibilities: 

• Recombinant virus engineering and performing protocol based R&D experiments.
• Planning and conducts a wide variety of innovative or pilot research studies, laboratory tasks, and experiments, data analysis according to protocols and under CTO's guidance.
• SOPs writing and review. 
• Provides updates on research progress and makes contribution to scientific literature and conferences, Preclinical studies PK/PD studies (in vitro and in vivo).
• Prepar draft study reports, summeries, protocols, and quantitiative analyses under supervision.
• Perform regular cell culture and virus related lab work and Laboratory equipments monitoring.

Associate Member, American Association for Cancer Research.

Global Outreach Member, American Society of Microbiology.

Member, Swedish Society of Virology.

Member, GMA, Graduate Microbiology Association, Bangladesh.

Executive Committee Member, Bangladesh Society of Microbiologist 

Cancer Immunotherapy, Oncolytic Virotherapy, CAR-T, NK Cell Therapy, Immune Checkpoint Inhibitors, Cancer Epidemiology, Biosimilar, Vaccine Development, Antimicrobial resistance and Commercially valuable enzymes.